CR20250077A - Derivados de co-cristales de 4-[4-[3-cloro-4-[1-(2-piridil)-2-hidroxi-etoxi]pirazolo[1,5-a]piridin-6-il]-5-metil-triazol-1-il]piperidina-1-carbonitrilo con ácido gálico y amida nicotínica - Google Patents

Derivados de co-cristales de 4-[4-[3-cloro-4-[1-(2-piridil)-2-hidroxi-etoxi]pirazolo[1,5-a]piridin-6-il]-5-metil-triazol-1-il]piperidina-1-carbonitrilo con ácido gálico y amida nicotínica

Info

Publication number
CR20250077A
CR20250077A CR20250077A CR20250077A CR20250077A CR 20250077 A CR20250077 A CR 20250077A CR 20250077 A CR20250077 A CR 20250077A CR 20250077 A CR20250077 A CR 20250077A CR 20250077 A CR20250077 A CR 20250077A
Authority
CR
Costa Rica
Prior art keywords
pyrazolo
carbonitrile
triazol
pyridin
piperidine
Prior art date
Application number
CR20250077A
Other languages
English (en)
Inventor
Kuminek Gislaine
a peterson Jeffrey
Andrew Coates David
Raquel Hilden Lori
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20250077A publication Critical patent/CR20250077A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con formas cocristalinas de 4- [4-[3-cloro-4-[1- (5-fluoro-2-piridil)-2-hidroxietoxi]pirazolo[1,5-a]piridin-6-il]-5-metil-triazol-1-il] piperidin-1-carbonitrilo, R-enantiómero (“Isómero 2”), con ácido gálico (I), y a formas cocristalinas de 4-[4-[3-cloro-4-[1-(2-piridil)-2-hidroxietoxi]pirazolo[1,5-a] piridin-6-il]-5-metil-triazol-1- il]piperidin-1-carbonitrilo, R-enantiómero (“Isómero A”), con ácido gálico o amida de nicotina (II) Los compuestos son crecimiento de fibroblastos inhibidores del receptor del factor 3 (FGFR3) para uso en métodos de tratamiento, p. ej., cáncer. Como se proporciona en la presente descripción también se proporcionan métodos para la preparación de dichas formas cocristalinas.
CR20250077A 2022-09-07 2023-09-06 Derivados de co-cristales de 4-[4-[3-cloro-4-[1-(2-piridil)-2-hidroxi-etoxi]pirazolo[1,5-a]piridin-6-il]-5-metil-triazol-1-il]piperidina-1-carbonitrilo con ácido gálico y amida nicotínica CR20250077A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263404232P 2022-09-07 2022-09-07
PCT/US2023/073508 WO2024054814A1 (en) 2022-09-07 2023-09-06 Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxy-ethoxy]pyrazolo[1,5-a]pyridin-6-yl]-5-methyl- triazol-1-yl]piperidine-1 -carbonitrile derivatives with gallic acid and nicotine amide

Publications (1)

Publication Number Publication Date
CR20250077A true CR20250077A (es) 2025-04-02

Family

ID=88204177

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250077A CR20250077A (es) 2022-09-07 2023-09-06 Derivados de co-cristales de 4-[4-[3-cloro-4-[1-(2-piridil)-2-hidroxi-etoxi]pirazolo[1,5-a]piridin-6-il]-5-metil-triazol-1-il]piperidina-1-carbonitrilo con ácido gálico y amida nicotínica

Country Status (18)

Country Link
US (1) US20240116932A1 (es)
EP (1) EP4584270A1 (es)
JP (2) JP7541606B2 (es)
KR (1) KR20250057022A (es)
CN (1) CN120187720A (es)
AR (1) AR130417A1 (es)
AU (1) AU2023338199A1 (es)
CA (1) CA3266872A1 (es)
CL (1) CL2025000596A1 (es)
CO (1) CO2025002467A2 (es)
CR (1) CR20250077A (es)
DO (1) DOP2025000054A (es)
IL (1) IL319342A (es)
JO (1) JOP20250053A1 (es)
MX (1) MX2025002687A (es)
PE (1) PE20251400A1 (es)
TW (1) TWI862146B (es)
WO (1) WO2024054814A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025259519A1 (en) 2024-06-13 2025-12-18 Eli Lilly And Company Activation of egfr/her2/3 in cancer after treatment with an inhibitor of fibroblast growth factor receptor 3 (fgfr3)
WO2026037249A1 (zh) * 2024-08-13 2026-02-19 海思科医药集团股份有限公司 取代杂环类衍生物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2412357T3 (es) * 2005-12-08 2013-07-11 New Form Pharmaceuticals Inc. Cocristales de metronidazol
PH12012000132B1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
CN102964384B (zh) * 2012-11-09 2015-06-24 中山大学 阿德福韦酯没食子酸共晶及其制备方法和组合物
WO2019160806A2 (en) * 2018-02-13 2019-08-22 Transgenex Nanobiotech, Inc. Novel crystalline forms of tamibarotene for treatment of cancer
JP2022515198A (ja) * 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
CN111574359A (zh) * 2019-02-19 2020-08-25 愈磐生物科技（苏州）有限公司 乐伐替尼-没食子酸共晶晶型及其应用
CN113943284B (zh) * 2020-07-15 2023-12-19 中国医学科学院药物研究所 盐酸吡格列酮没食子酸共晶及制备方法和其组合物与用途
IL304886B2 (en) 2021-03-04 2025-08-01 Lilly Co Eli Fgfr3 inhibitor compounds

Also Published As

Publication number Publication date
WO2024054814A1 (en) 2024-03-14
CL2025000596A1 (es) 2025-04-25
AR130417A1 (es) 2024-12-04
TW202428260A (zh) 2024-07-16
PE20251400A1 (es) 2025-05-22
JP2024153948A (ja) 2024-10-29
TWI862146B (zh) 2024-11-11
IL319342A (en) 2025-05-01
KR20250057022A (ko) 2025-04-28
CA3266872A1 (en) 2024-03-14
DOP2025000054A (es) 2025-03-31
CO2025002467A2 (es) 2025-03-17
JP2024037713A (ja) 2024-03-19
US20240116932A1 (en) 2024-04-11
MX2025002687A (es) 2025-04-02
AU2023338199A1 (en) 2025-03-20
JOP20250053A1 (ar) 2025-03-06
CN120187720A (zh) 2025-06-20
JP7541606B2 (ja) 2024-08-28
EP4584270A1 (en) 2025-07-16

Similar Documents

Publication Publication Date Title
DOP2025000054A (es) Derivados de co-cristales de 4-[4-[3-cloro-4-[1-(2-piridil)-2-hidroxi-etoxi]pirazolo[1,5-a]piridin-6-il]-5-metil-triazol-1-il]piperidina-1-carbonitrilo con ácido gálico y amida nicotínica
ECSP22011086A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
MX2022012780A (es) Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados.
CO2021017981A2 (es) Inhibidores heterobicíclicos de mat2a y métodos de uso para el tratamiento del cáncer
Zhang et al. Essential role for synaptopodin in dendritic spine plasticity of the developing hippocampus
CN1947717B (zh) 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
AR119207A1 (es) DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
UY27811A1 (es) 3-aminopirazoles n-sustituidos como inhibidores para el tratamiento de los desórdenes proliferativos de las células.
CL2011000880A1 (es) Compuestos derivados de pirazolo[1,5-a]pirimidin-3-il, inhibidores de tirosina de la familia trk cinasa; proceso para la preparacion de los compuestos; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del dolor y del cancer.
HUP0102240A2 (hu) Indigoid biszindolszármazékok alkalmazása ciklinfüggő kinázok gátlására szolgáló gyógyszer előállítására
AR038202A1 (es) Compuestos de indazol utiles como inhibidores de la proteina quinasa
GT200900056A (es) Benzoxazoles y oxazolopiridinas utiles como inhibidores de la quinasa janus
Hu et al. Indirubin-3-oxime effectively prevents 6OHDA-induced neurotoxicity in PC12 cells via activating MEF2D through the inhibition of GSK3β
MX2021009444A (es) Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7.
Kranz et al. Phosphodiesterase type 4 inhibitor rolipram improves survival of spiral ganglion neurons in vitro
Lv et al. Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment
Li et al. Sin1/mTORC2 regulate B cell growth and metabolism by activating mTORC1 and Myc
BR112023011451A2 (pt) Inibidores de alk-5 e seus usos
Wu et al. Melatonin‐mediated upregulation of GLUT1 blocks exit from pluripotency by increasing the uptake of oxidized vitamin C in mouse embryonic stem cells
KR20230049620A (ko) 교류 전기장에 대한 암세포 민감도를 증가시키기 위한 방법 및 조성물
EA202190323A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk
CL2025002940A1 (es) Derivados de 5-amino-6,8-dihidro-1h-furo[3,4-d]pirrolo[3,2-b]piridin-2-carboxamida como inhibidores cooperativos con mta de prmt5
CN119454695A (zh) Csf1r激酶抑制剂及其用途
Belcher et al. Estrogen and soy isoflavonoids decrease sensitivity of medulloblastoma and central nervous system primitive neuroectodermal tumor cells to chemotherapeutic cytotoxicity
Bortolotto et al. Proneurogenic effects of trazodone in murine and human neural progenitor cells